AI Terminal

MODULE: AI_ANALYST

Interactive Q&A, Risk Assessment, Summarization

MODULE: DATA_EXTRACT

Excel Export, XBRL Parsing, Table Digitization

MODULE: PEER_COMP

Sector Benchmarking, Sentiment Analysis

SYSTEM ACCESS LOCKED

Authenticate / Register Log In

Medistim

Earnings Release • Feb 25, 2022

3662_rns_2022-02-25_8863cee0-59b5-40a6-a18e-d675b14b96dd.html

Earnings Release

Open in Viewer

Opens in native device viewer

4th quarter and preliminary year end results for 2021

All time high sales for a quarter, ending at MNOK 112.7 (MNOK 94.2), an increase of 19.7%. Full year 2021 sales ended at a record of MNOK 427.3 (MNOK 363.1). Currency neutral sales of own products increased by 38% for the quarter and 28% for the year.

Operating result (EBIT) for the quarter ended at MNOK 19.5 (MNOK 22.1). Operating result for 2021 ended at MNOK 116.3 MNOK 95.5), a 21.8% increase. This is the best operating result for a year ever. Cashflow from operations was a solid MNOK 127.5 for the year. Cash by the end of the year was MNOK 129.5.

Expert consensus paper published in the world-renowned journal Circulation with strong advocacy for the routine use of flow measurement technology.

The Board will suggest to the General Meeting a dividend of NOK 3.75 per share.